Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group box 1 pseudogene 27 (HMGB1P27)
- Target
- HMGB1P27
- Molecular classification
- Pseudogene, Other (not receptor, not enzyme, not transcription factor, not transporter, not ion channel, not histone modification)
01
Overview
High mobility group box 1 pseudogene 27 (HMGB1P27) is a human pseudogene located within the genome and classified in the NCBI Gene database[4]. By definition, pseudogenes are DNA sequences resembling functional genes but which have lost the ability to encode functional proteins due to mutations, regulatory changes, or incomplete transcription/translation[5]. While some pseudogenes in other gene families may exert regulatory effects at the RNA level (for example, by acting as miRNA sponges or influencing parent gene expression[2][3]), there is currently no published evidence for functional involvement of HMGB1P27 in human disease, biological processes, or drug interactions. Thus, HMGB1P27 should not be considered a canonical therapeutic target.
- Other names
- High mobility group box 1 pseudogene 27HMGB1P27
02
Mechanism of action
None. There is no described mechanism of action for drugs targeting HMGB1P27.
03
Biological functions
No direct protein or functional activity.Pseudogenes can sometimes act as competitive endogenous RNAs (ceRNAs) that may regulate expression of their parental genes by sponging microRNAs (miRNAs), but this has not been described for HMGB1P27 specifically[2][3]. Other pseudogenes of high mobility group genes (such as HMGA1-P) have shown such activity, but there is no reported evidence for HMGB1P27’s similar role.
04
Disease associations
None specific to HMGB1P27.Other high mobility group pseudogenes (like HMGA1-p) may affect disease via transcript-level regulation, but HMGB1P27 itself has not been linked to any diseases as of the current knowledge base[4][5].
05
Safety considerations
None. As HMGB1P27 is not a therapeutic target, safety is not a relevant issue.
06
Interacting drugs
None. There are no known drugs interacting with HMGB1P27.
07
Biomarkers
None. HMGB1P27 is not a biomarker for any disease or condition.
Beyond the preview
Go deeper on High mobility group box 1 pseudogene 27 (HMGB1P27).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on High mobility group box 1 pseudogene 27 (HMGB1P27).